News
-
Berkley Pharma & Life Science are currently seeking a QA Manager/QP for our client a Global pharmaceutical company based in Dublin. Ref: 5040183 Role/Opportunity: • To manage and lead the Pilot Plant site Quality Assurance… Read more . . .
-
Berkley Pharma & Life Science are currently seeking an Equipment Senior Scientist for our client, a leading pharmaceutical company based in Dublin. Ref: 5040180 Role/Opportunity: • Seeking an experienced Manufacturing Equipment specialist with a good… Read more . . .
-
Consort Medical has announced record revenue and profits for the year ending April 30, 2012, including a 12% increase in revenue for its Bespak division, which manufactures metered dose inhaler valves and actuators as well… Read more . . .
-
Contract particle characterization specialist Gateway Analytical has announced that it will host the 2012 Inhalation and Nasal Technology Focus Group (INTFG) Annual Fall Symposium on September 7, 2012 at the Pittsburgh North Marriott in Cranberry,… Read more . . .
-
Submit poster abstracts by August 19, 2012 at the INTFG submission site. Submissions on any inhalation or nasal drug technology topic are welcome. More information. Read more . . .
-
Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis.… Read more . . .
-
Entries submitted to several student inhaler and medical device design contests over the past year envision some radical changes in inhaler design. These concepts, created by students who range in age from primary school through… Read more . . .
-
Pharmaxis has submitted an NDA for Bronchitol inhaled dry powder mannitol for the treatment of cystic fibrosis to the FDA. Pharmaxis CEO Dr Alan Robertson said, “The submission marks the second of two key milestones… Read more . . .
-
Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection… Read more . . .
-
According to Insmed, the company has decided to focus on European and Canadian studies of its Arikace liposomal amikacin for inhalation and to put a US Phase 3 study on the back burner. The CLEAR-108… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.